Actuate therapeutics announces inclusion in the russell 3000® and russell 2000® indexes

Chicago and fort worth, texas, june 16, 2025 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), announced today that the company will be added to the russell 3000® index, with automatic inclusion in the russell 2000® index, effective after the u.s. market close on june 27, as part of the 2025 russell indexes annual reconstitution. the inclusion follows the initial announcement on friday, may 23, and the latest update on friday, june 13, 2025, in connection with the annual reconstitution of the russell u.s. indexes.
ACTU Ratings Summary
ACTU Quant Ranking